Advertise on podcast: Peptides Explained

Weight loss is not the same thing as fat loss. A 2025 monkey study combining semaglutide with experimental myostatin and activin A antibodies raised the possibility of protecting lean mass while losing fat. Now COURAGE phase 2 data provide a human lean-mass preservation signal — alongside serious safety and tolerability concerns with the triple combination. John Garrett, RN, separates animal results, company-reported human data, body-composition measurements, and clinical outcomes. Trevogrumab and garetosmab are investigational monoclonal antibodies, not approved muscle-preserving peptides. Educational content only. Research links: https://doi.org/10.1038/s41467-025-59485-9 ; https://clinicaltrials.gov/study/NCT06299098 ; https://newsroom.regeneron.com/news-releases/news-release-details/phase-2-courage-trial-confirms-trevogrumab-prevents-lean-mass

Introducing Adam Grant: How to Feel Less Lonely and Build Deeper Connections from The Oprah Podcast. Follow the show: The Oprah Podcast BUY THE BOOK! Vibe: The Secrets of Strong Connections in a Lonely World  https://link.amazon/B0cQd5ZWG Adam Grant, bestselling author and organizational psychologist joins the Podcast to talk about his new book Vibe: The Secrets of Strong Connections in a Lonely World. Adam Grant explains the science behind human connection and the surprising secrets about what it means to create a “vibe” with another person. He shares why some people instantly click, while others struggle to connect. Oprah and Adam talk to NASA astronaut Cady Coleman who explains how she learned to vibe and ultimately trust members of her crew before a near shuttle disaster in outer space. NBA Legend Joe Dumars explains how he creates a vibe on his professional basketball team, even though he’s known for seeking out the most difficult and volatile players. Adam Grant talks about the “snap judgements” we all make in our lives, including one he made with vulnerability researcher Brené Brown that caused a four year rift between them. From marriage, family and friendship Adam Grant offers some surprising discoveries for anyone looking for deeper connections, stronger bonds and healthy ways to Vibe. 00:00:00 - Welcome Adam Grant, author of “Vibe” 00:05:00 - Human connection is missing 00:06:00 - Pebbling definition 00:08:38 - Rapid high-quality connection  00:10:20 - Welcome Astronaut Cady Coleman 00:15:45 - Connection saves their lives in space?  00:17:47 - Vibing with coworkers 00:20:00 - Welcome NBA legend Joe Dumars  00:22:30 - Joe on working with difficult players  00:25:20 - Friction can be good  00:27:30 - Finding genuine friendship 00:30:45 - Happier with friends than family 00:31:30 - Judgements can block connection 00:32:30 - Adam Grant and Brene Brown  00:34:50 - Adam’s marriage  Follow Oprah Winfrey on Social: https://www.instagram.com/oprahpodcast/ https://www.facebook.com/oprahwinfrey/ DISCLAIMER: Please note, this is an independent podcast episode not affiliated with, endorsed by, or produced in conjunction with the host podcast feed or any of its media entities. The views and opinions expressed in this episode are solely those of the creators and guests. For any concerns, please reach out to [email protected].

True-Sciences.com use code Pep20 for 20% off your first order Dr. Hany Demian joins John Garrett for a conversation about chronic pain, injury recovery, regenerative medicine, and where peptides may fit in patient care. Drawing on his clinical experience, Dr. Demian discusses how he approaches patients with different needs, why he avoids a "kitchen sink" approach, and why sleep, nutrition, exercise, and careful assessment still matter. They also talk about clinical judgment, patient safety, and situations where peptides may not be appropriate. The conversation includes clinical anecdotes and personal perspectives. These do not establish that a peptide is safe or effective. Evidence for compounds such as BPC-157 and TB-500 remains limited. This episode is for educational purposes and is not individualized medical advice.

BPC-157 is back in the compounding-policy conversation—but what does HHS's new notice actually change, and what does the human evidence show? In this revisit, John Garrett looks at BPC-157's proposed biology, the three small published human reports, new clinical-trial registry entries, the FDA advisory committee's recommendation, and HHS's October 30 interim enforcement-discretion policy. The published human record remains small and very low certainty. For BPC-157, the HHS policy identifies the acetate form and specified dosage forms under limited Section 503A circumstances. It is conditional and interim; it does not make BPC-157 FDA-approved, add it to the 503A Bulks List, or establish that it works. We also explain why the anti-doping rules are a separate question. This episode is for informational purposes only and is not medical advice. Research and policy details were checked October 30, 2026; verify current status before publication.

What if the future of regenerative medicine isn't just about stem cells—but the biological messages those cells send? In this episode of Peptides Explained, John Garrett sits down with Sanjiv Lal, founder of Cell Factor and co-founder of Regen Therapy, to explore the emerging science of secretomes, cellular communication, and regenerative medicine. Sanjiv shares his personal journey from pharmaceutical sciences and molecular diagnostics to becoming a patient facing significant health challenges. That experience sparked his interest in cell-free regenerative technologies and the biological signaling systems involved in tissue repair, inflammation, and aging. Together, John and Sanjiv explore: Secretome science: What secretomes are and how they differ from stem cells and exosomes. Cellular communication: How peptides, growth factors, cytokines, and extracellular vesicles influence biological signaling. Cell Factor: Sanjiv's explanation of the technology, manufacturing process, and potential applications. Mitochondrial health: The relationship between cellular energy, inflammation, and biological function. Healthspan vs. lifespan: Why extending healthy, functional years matters as much as extending life. Peptides and longevity: Sanjiv's personal experience with Cell Factor, SS-31, MOTS-c, and other interventions. The future of healthcare: The potential role of preventive medicine, personalized diagnostics, and emerging regenerative technologies. Sanjiv also discusses his own health improvements and his vision for expanding access to regenerative medicine through Regen Therapy and related ventures. The bigger question: Can scientists harness cellular signaling to improve human health, and what clinical evidence will be needed to demonstrate that these approaches are safe and effective? This is a conversation about scientific possibility, innovation, and taking a more active role in long-term health. Learn more: Cell Factor: https://cell.health/ RegenTherapy https://regentherapy.com Important disclaimer: This episode is for educational purposes only and does not constitute medical advice. Cell Factor and the experimental approaches discussed should not be considered proven treatments for kidney disease, diabetes, aging, or other medical conditions. Personal experiences are not controlled clinical evidence. Consult a qualified healthcare professional before making treatment decisions.

True-Sciences.com Use Code Pep20 for 20% off. A careful look at CJC-1295: the growth-hormone pathway, the distinction between DAC and no-DAC naming, what small human studies measured, the terminated Phase 2 trial, current FDA compounding information, the unproven CJC-1295/ipamorelin combination claims, and WADA's 2026 rules. The evidence supports a hormone effect for the long-acting DAC-modified compound; it does not establish the benefits often marketed for consumer products. Educational content only; not medical advice. Snapshot checked October 19, 2026.

Seed oils may be hiding in more of your everyday foods than you realize. In this episode of Peptides Explained, host John talks with Cherie Calbom, MS—known as the Juice Lady—about seed oils, cooking fats, inflammation, and how to make more informed choices at the grocery store and when dining out.Cherie discusses how common seed oils are processed, why she recommends checking ingredient labels, and which alternatives she uses, including olive oil, avocado oil, coconut oil, ghee, and beef tallow. They also talk about omega-6 and omega-3 balance, cooking with different fats, and practical ways to make food swaps without giving up flavor.The conversation explores the history of seed oils and changing ideas about dietary fat and cholesterol. Cherie shares tips for spotting oils in packaged foods and describes resources for people who want to learn more, including her book The Truth About Seed Oils. Topics include: seed oils, cooking fats, inflammation, omega-6 and omega-3, food labels, nutrition, and healthy cooking.

Eli Lilly is taking legal action against businesses selling products labeled retatrutide. What do the lawsuits actually establish—and what don't they? John Garrett separates pending legal allegations from court findings, reviews the human trial evidence for the investigational triple agonist, and explains why molecular identity, purity, and pharmaceutical equivalence are not interchangeable. We also examine FDA restrictions, consumer safety, and the implications for clinics, vendors, and independent educators. Educational only; not medical or legal advice. Retatrutide is not FDA-approved. Sources: NEJM DOI 10.1056/NEJMoa2301972; FDA unapproved GLP-1 drug concerns; ClinicalTrials.gov NCT05929066 and NCT05882045.

Can peptide biology protect the brain from vascular damage? John follows a question that started with Vesugen into the biology of vascular cognitive impairment—endothelial dysfunction, hypoperfusion, blood-brain-barrier injury, mitochondrial stress, inflammation and neuronal damage. The episode maps Cerebrolysin, SS-31/elamipretide, ARA-290/cibinetide, Semax, Vesugen and GLP-1 receptor agonists onto different points in that cascade, then asks the question that matters: what does the human evidence actually support? Cerebrolysin provides the biggest surprise, with randomized vascular-dementia trials—but still low-certainty evidence. Educational only; not medical advice.

Everyone keeps calling belly fat "visceral fat." That is not how anatomy works. In this crossover episode, John breaks down the difference between visceral and subcutaneous fat, why visceral adipose tissue matters metabolically, how it is actually measured, what waist circumference can and cannot tell you, and what the evidence says about GLP-1 therapies and tesamorelin.

Vesugen is only three amino acids long: lysine, glutamate, and aspartate — KED. Yet it is promoted as a vascular bioregulator that may support endothelial health and even "rejuvenate" aging blood vessels. In this episode, John Garrett looks at what the endothelial research actually measured, the proposed gene-regulation mechanism, a small human blood-flow report, and the large gap between an interesting cell signal and a proven cardiovascular therapy. No hype. No dismissal. Just the biology, the evidence, and what remains unknown. INSTAGRAM CAPTION Three amino acids. K. E. D. And somehow that became a claim about "rejuvenating" aging blood vessels. Vesugen is one of the more interesting Khavinson bioregulator peptides because there is actual published endothelial-cell research behind the concept. But there is a big difference between: changing a cell marker improving endothelial function and preventing cardiovascular disease. In the new episode of Peptides Explained, I break down the mechanism, the human signal, the evidence gaps, and the question that matters most: Can Vesugen actually make aging blood vessels younger — or is the marketing way ahead of the science? Educational only. Not medical advice. #PeptidesExplained #Vesugen #KEDPeptide #Peptides #Longevity #VascularHealth #EndothelialHealth #CardiovascularHealth #HealthyAging #Biohacking #PeptideScience #MedicalScience

FLGR-242 is being called a smarter, longer-acting follistatin. John examines the advertised construct, the activin-sparing and 19-day half-life claims, the difference between pathway evidence and product evidence, and why transformation photos cannot establish pharmacology or safety.

Follistatin can bind myostatin—one of the body's major restraints on skeletal-muscle growth. Animal studies are dramatic, and small human gene-therapy studies have produced encouraging signals in serious muscle disease. But is a vial labeled "Follistatin-344" equivalent to the therapy used in those trials? John Garrett explains FST288, FST315, and FST344; the myostatin/activin pathway; the difference between gene therapy and recombinant protein; the evidence for muscle size versus function; and the key safety and product-identity questions. Follistatin is not an FDA-approved muscle-building medication. Educational content only; not medical advice. Explore the free Peptides Explained app: https://app.peptidesexplained.info

Glutathione gets called the "master antioxidant," and the underlying biology really is important. But does that mean oral supplements, liposomal products or glutathione IVs deliver the sweeping detox, energy, immune and anti-aging benefits often attached to them? John breaks down glutathione biology, the GSH/GSSG cycle, oral human data, NAC, skin-related research and the gap between changing a biomarker and changing a meaningful health outcome. The episode also covers the 2026 FDA warning and recalls involving compounded injectable glutathione and elevated endotoxin levels. The key question: where does established biology end and wellness marketing begin? Educational only. Not medical advice.

For more information on Research Peptides go to PeptidesExplained.info/OfflinePeptides Is taking smaller GLP-1 doses multiple times per week actually "microdosing"? Not necessarily. This episode separates split dosing from true dose reduction and explains the pharmacokinetic logic using semaglutide, tirzepatide, and retatrutide. John breaks down half-life, peaks, troughs, total exposure, and why changing the schedule does not automatically mean using less drug. We also examine the major evidence gap: once-weekly dosing has a strong clinical foundation for semaglutide and tirzepatide, while retatrutide remains investigational — and direct randomized evidence showing routine split dosing is superior is not established. Educational only. No individualized dosing protocols are provided.